Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.
  • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial act
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
    (Date:9/15/2014)... FRANCISCO , Sept. 15, 2014 ... studies presented at the American Society for Radiation ... its Decipher® Prostate Cancer Classifier, a genomic test ... influence treatment decisions and improve patient outcomes for ... These presentations follow a recently published study that ...
    (Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data on the ... report provides value, in millions of US dollars, ... dollars) within market segments Invasive Body Contouring Devices ... Radio Frequency-Assisted Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) ...
    Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
    ... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
    ... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
    Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
    (Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... leading to strong heart fitness can delay a man,s onset ... new study suggests. Blood pressure naturally increases as people ... But men with strong cardio-fitness don,t start drifting toward high ... sedentary men usually experience the early signs of high blood ...
    (Date:9/16/2014)... 15, 2014Mobility is equally preserved in cancer patients suffering ... single dose of 10 Gy of radiation therapy (RT), ... 4 Gy of RT each, according to research presented ... 56th Annual Meeting. , Malignant spinal cord compression ... bone involvement that occurs when a tumor,s secondary deposit ...
    (Date:9/16/2014)... some of Australia,s best fast bowlers, track and field ... thanks to a new training technique discovered by a ... of Health and Biomedical Innovation, with support from the ... Sport Science Research, has studied the run-ups of elite ... jump and pole vault and found the vertical objects ...
    (Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
    (Date:9/16/2014)... Transparency Market Research, a U.S. - ... care market is expected to report an approximate value ... Care Market (By Product Type - Skin Whitening/ Lightening ... and Masks and Others (fade creams, pore strips and ... Forecast 2013 – 2019,’ is now available for sale ...
    Breaking Medicine News(10 mins):Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Getting the jump on competitors: QUT study 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
    ... N.Y., JAN. 5, 2009 Only 17 percent of ... are taking a multivitamin containing folic acid daily, according ... to focus on this population. , Folic acid ... of the brain and spine such as spina bifida ...
    ... Jan. 5 Only 17 percent of Spanish-speaking women ... a multivitamin containing folic acid daily, according to the ... on this population. Folic acid can prevent neural tube ... spine such as spina bifida and anencephaly, which are ...
    ... Volcano Corporation,(Nasdaq: VOLC ), a leader ... diagnosis and treatment of coronary and peripheral artery,disease, will ... to,discuss its acquisition of Axsun Technologies, Inc., that was ... The teleconference call and webcast will begin at 1 ...
    ... Conference on Cell Therapy for Cardiovascular Disease (IC3D) will ... organ injury. The session will include new data on ... cells for stroke patients, and treating Parkinson,s disease with ... include the first human data using special bone marrow ...
    ... Newswire Staff Volunteer Time As Part of ... Jan. 5 Ronald McDonald House of Cleveland ... non-profit organizations serving the Cleveland community, were the ... from PR Newswire,s Cleveland staff in 2008, PR ...
    ... OF THE AMERICAN SOCIETY OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., ... the American Society of Plastic Surgeons:Can The US Really ... that while health care is one of the strongest ... sustainable reduction is US health care spending is not ...
    Cached Medicine News:Health News:Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says 2Health News:First Nationwide Folic Acid Survey of Spanish-Speaking Women Finds Most Are Missing Benefits, March of Dimes Says 2Health News:First Nationwide Folic Acid Survey of Spanish-Speaking Women Finds Most Are Missing Benefits, March of Dimes Says 3Health News:Reminder: Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: